Cellares Selects Technology Providers to Expand Cell Q’s Capabilities 

Cellares, an Integrated Development and Manufacturing Organization (IDMO), has entered multiple strategic technology partnerships to advance the Cell Q, the company’s fully automated quality control testing platform purpose-built to match the commercial-scale throughput for cell therapy manufacturing. 

Cell Q is a modular, configurable QC platform that automates and streamlines labor-intensive, in-process and release assays. A single Cell Q system can support automated QC release testing of up to 6,000 cell therapy batches per year, providing end-to-end scalability, according to the company. In collaboration with technology providers Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences, and AltemisLab, Cellares aims to streamline all critical QC testing operations for Cell Q, from high-throughput sample preparation to real-time data tracking and reporting, at a fraction of the cost and operational burden of traditional approaches.

With changing demands for QC testing, Cellares drove product development and integration of technology providers across five key domains – liquid handling, liquid property characterization, flow cytometry, synthetic controls, and sample tracking – to co-develop specialized hardware, software, and reagents designed to integrate seamlessly into the Cell Q platform.

                  •               Tecan: Delivered advanced liquid handling systems and hardware-software interfaces to enable scalable, reproducible workflows and results. 

                  •               Advanced Instruments: Integrated and automated verification of liquid handling, performance, and calibration with its Artel portfolio.

                  •               Cytek Biosciences: Optimized fully automated full spectrum flow cytometry workflows, from plate mapping through takedown.

                  •               Slingshot Biosciences: Developed cell mimics and ready-to-use flow cytometry panels that enable reproducible results across sites, operators, and instruments.

                  •               AltemisLab: Integrated pre-barcoded cryovials, tube decapping, and automated thawing to preserve Chain of Identity (COI) and Chain of Custody (COC) across the QC lifecycle.



Cell Q aims to provide a ready-made infrastructure to support GMP compliance, digital traceability, and audit-readiness from the start. For early-stage developers, this helps to de-risks tech transfer and accelerates IND timelines. For commercial developers, it helps reduce labor dependency and batch failure risk while enabling global scale-up without compromising quality.

“Cell Q was built to match the commercial manufacturing throughput of the Cell Shuttle,” said Fabian Gerlinghaus, CEO and Co-Founder of Cellares. “With fewer handoffs, less failure, and more importantly, better data quality.”